BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P, Giustina G, Ruol A. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver. 1990;10:141-146. [PMID: 2385155 DOI: 10.1111/j.1600-0676.1990.tb00449.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829-834. [PMID: 15178498 DOI: 10.1016/j.amjmed.2003.12.040] [Cited by in Crossref: 199] [Cited by in F6Publishing: 171] [Article Influence: 11.7] [Reference Citation Analysis]
2 Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31 Suppl 1:104-110. [PMID: 21205146 DOI: 10.1111/j.1478-3231.2010.02396.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
3 Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol. 2010;16:5447-5451. [PMID: 21086562 DOI: 10.3748/wjg.v16.i43.5447] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
4 Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177-1185. [PMID: 22871500 DOI: 10.1016/j.jhep.2012.07.031] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
5 Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma. 2008;49:939-947. [PMID: 18464113 DOI: 10.1080/10428190801975568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
6 Murata K, Sugimoto K, Shiraki K, Nakano T. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J Gastroenterol 2005;11:6848-52. [PMID: 16425395 DOI: 10.3748/wjg.v11.i43.6848] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
7 Mels GC, Bellati G, Leandro G, Brunetto MR, Vicari O, Borzio M, Piantino P, Fornaciari G, Scudeller G, Angeli G. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver. 1994;14:175-181. [PMID: 7968277 DOI: 10.1111/j.1600-0676.1994.tb00071.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 1.5] [Reference Citation Analysis]
8 Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39 Suppl 1:S50-S58. [PMID: 14708678 DOI: 10.1016/s0168-8278(03)00139-9] [Cited by in Crossref: 132] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
9 Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
10 Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003-1016. [PMID: 16984494 DOI: 10.1111/j.1365-2036.2006.03081.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 5.9] [Reference Citation Analysis]
11 Colloredo Mels G, Bellati G, Leandro G, Brunetto MR, Vicari O, Piantino P, Borzio M, Angeli G, Ideo G, Bonino F. Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol Suppl 1993;8:203-11. [PMID: 8260865 DOI: 10.1007/978-3-7091-9312-9_20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Kamitsukasa H, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, Okamoto H. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol 2015;87:589-600. [PMID: 25612181 DOI: 10.1002/jmv.24115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, Doutreloigne J, Bogaerts V, Wong BC, Fan ST, Lai CL. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003;36:979-984. [PMID: 12684909 DOI: 10.1086/374226] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Mod Pathol. 2000;13:679-704. [PMID: 10874674 DOI: 10.1038/modpathol.3880119] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
15 Magalhães MJ, Pedroto I. Hepatitis B Virus Inactive Carriers: Which Follow-up Strategy? GE Port J Gastroenterol 2015;22:47-51. [PMID: 28868373 DOI: 10.1016/j.jpge.2015.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Sarin S, Kumar M, Tyagi P. HBV carrier or chronic HBV infection: Need for change in terminology. J Gastroenterol Hepatol 2004;19:S103-7. [DOI: 10.1111/j.1440-1746.2004.03654.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669-674. [PMID: 12399235 DOI: 10.1016/s0168-8278(02)00267-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
19 Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-S165. [PMID: 19399803 DOI: 10.1002/hep.22945] [Cited by in Crossref: 375] [Cited by in F6Publishing: 314] [Article Influence: 31.3] [Reference Citation Analysis]
20 Liu C, Chen P, Lai M, Kao J, Chen D. Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. J Med Virol 2004;74:237-45. [DOI: 10.1002/jmv.20176] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
21 Kuo R, Cheng W, Lien W, Yang T. A medical cost estimation with fuzzy neural network of acute hepatitis patients in emergency room. Computer Methods and Programs in Biomedicine 2015;122:40-6. [DOI: 10.1016/j.cmpb.2015.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
22 Li H, Zhang H, Chen L, Chen Y, Chen L, Ren H, Hu H. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015;39:80-92. [DOI: 10.1016/j.clinre.2014.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]